Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7567132 and Atezolizumab · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part I: RO7567132 Dose Escalation With or Without Atezolizumab | EXPERIMENTAL | - |
| Part II: RO7567132 Backfill With Atezolizumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| RO7567132 and Atezolizumab | DRUG | RO7567132 will be administered either as monotherapy or in combination with atezolizumab at a dose and schedule as specified for the respective cohort. |
Inclusion Criteria: * Male or female participants aged ≥18 years * Body weight \> 40 kilograms (kg) * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 and Life expectancy of at least 12 weeks * Participants with advanced and/or metastatic solid tumors * Availability and willin...
RO7567132 and Atezolizumab is an investigational combination being studied for the treatment of advanced solid tumors in patients with cancer. It is currently in Phase 1 clinical development, evaluated as a single agent and in combination with Atezolizumab in participants with advanced solid tumors.
RO7567132 and Atezolizumab is being developed by Roche Holding AG, a biopharmaceutical company. Roche is conducting a Phase 1 dose-escalation study of RO7567132 as a single agent and in combination with Atezolizumab in participants with advanced solid tumors.
RO7567132 and Atezolizumab is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. It is being studied in a dose-escalation trial for advanced solid tumors, with the trial currently active but not recruiting participants.
RO7567132 and Atezolizumab is being studied in clinical trial NCT06537310, a Phase 1 dose-escalation study as a single agent and in combination with Atezolizumab in participants with advanced solid tumors. The trial has an enrollment of 34 participants and is active but not recruiting.
RO7567132 and Atezolizumab is a combination regimen that includes Atezolizumab, but it is not the same as Atezolizumab alone. The study evaluates RO7567132 as a single agent and in combination with Atezolizumab, meaning the combination is a distinct investigational treatment being tested.